Executive Director, Radiology & Theranostics

Lead an integrated global Radiology & Theranostics organization spanning translational radiology, computational radiology, medical imaging, medical physics, nuclear medicine and translational science . This role will set and execute imaging strategy from preclinical through late clinical development, predominantly in oncology across solid tumors and hematologic malignancies and across therapy modalities, with a dditional support for trials beyond oncology. Key deliverables include development of imaging-based biomarkers for patient selection, target validation, pharmacodynamic assessment and treatment endpoints. Why this role Radiology is critical to diagnosing, staging and monitoring disease, but remains underused as a biomarker in drug development. Integrating radiology with pathology, proteomics, liquid biopsy and clinical data can accelerate endpoint development, patient-selection technologies, target validation and biomarker discovery. The longer-term opportunity is to use radiology and laboratory data to inform the right target, modality, dose, regimen and endpoint— ultimately improving patient outcomes. Competitors are already developing radiology-led multimodal biomarker platforms, making an enterprise-wide imaging strategy essential to strengthen delivery, science and innovation across the pipeline. Location: Gaithersburg MD or Kendall Square MA Key accountabilities Define and execute the enterprise strategy for Radiology & Theranostics across the oncology portfolio, from preclinical development through late-stage clinical trials. Establish a unified operating model, governance and investment roadmap for global imaging capabilities. Lead imaging strategy for clinical development and pivotal trials, including patient selection, target validation, pharmacodynamic assessment, response assessment, endpoint selection and regulatory alignment. Advance imaging-based biomarkers and radiomics for patient selection, pharmacodynamics, treatment endpoints and biomarker discovery. Earlier, consistent integration of imaging into preclinical, clinical development and indication plans. Lead Theranostics and Radioconjugate imaging strategy from preclinical development through Phase III, including dosimetry and study design. Integrate PET, nuclear medicine, medical physics and translational science capabilities, including external academic collaborations. Ensure imaging strategies are incorporated early into asset and indication plans across solid tumor , hematologic malignancy and selected non-oncology trials. Represent the function in senior governance, business-development evaluations and interactions with regulators and external experts. Recruit, develop and retain a high-performing, multidisciplinary global organization. Leadership scope The role is expected to provide strategic oversight across: Translational Radiology: clinical development imaging strategy, radiographic endpoints and imaging-based biomarkers from preclinical through late clinica l development Computational Radiology: radiomics, imaging AI and multimodal biomarkers Medical Imaging, Medical Physics & Translational Science: Theranostics , Radioconjugate and dosimetry Regional and external capabilities: including China and EU collaborations Measures of success One aligned Radiology & Theranostics strategy and governance model. Earlier, consistent integration of imaging into development plans. Increased use of validated imaging endpoints and biomarkers. Scalable radiomics data and AI infrastructure. Strong Theranostics and R adioconjugate development capabilities. Reduced duplication and improved collaboration across organizational boundaries. Experience Required MD, PhD or equivalent advanced degree in radiology, nuclear medicine, medical physics, biomedical imaging, oncology or a related discipline. Extensive leadership experience in pharmaceutical development, translational medicine or imaging sciences (minimum of 10&#43; years of relevant experience) . Demonstrated expertise in clinical imaging endpoints, imaging-based biomarkers, radiomics or t heranostics , including application to patient selection, target validation, pharmacodynamics and treatment endpoints. Strong understanding of oncology drug development across solid tumors and hematologic malignancies, therapy modalities and global regulatory expectations. </sp